A new survey assessing awareness of and attitudes about biosimilars among medical specialists and pharmacists in Ireland found that majority of such experts say that they are familiar or very familiar with the term “biosimilar,” but many general practitioners (GPs) were either unable to define or had never heard the term.
A new survey assessing awareness of and attitudes about biosimilars among medical specialists and pharmacists in Ireland found that a majority of such experts say that they are familiar or very familiar with the term “biosimilar,” but many general practitioners (GPs) were either unable to define or had never heard the term. Study authors Joan O’Callaghan, School of Pharmacy, University College, Cork, Ireland, and colleagues published the results of their survey online in the June 27, 2017 issue of Regulatory Toxicology and Pharmacology.
The study’s authors invited physicians to complete a questionnaire during April and May of 2016, and community pharmacists received a postal questionnaire in August of 2015. Responses were received from 268 GPs, 109 medical specialists, and 143 community pharmacists. The final analysis included responses from 102 medical specialists, 254 GPs, and 125 community pharmacists. Medical specialists included dermatologists, endocrinologists, gastroenterologists, hematologists, nephrologists, neurologists, oncologists, and rheumatologists.
Many medical specialists claimed to be very familiar, with a complete understanding (44%), or familiar, with a basic understanding (41%), of the term “biosimilar.” Although familiarity among medical specialists was high, the researchers found that this level of familiarity was not consistent across the 3 professions surveyed. GPs were the least familiar with the term, with 1 in 4 saying that they had never heard the term biosimilar—possibly because GPs are not directly involved in the prescribing of biological drugs. “However, GPs are certainly involved in the treatment of patients receiving biological medicines; therefore it is important that GPs are informed about biosimilars,” the authors note.
With 1 in 5 healthcare professionals who had previously heard the term “biosimilar” responding that they believed biosimilars to be the same thing as generic medications, the authors questioned the level of understanding of biosimilars among some healthcare professionals, and said that the survey exposed some misconceptions about fundamental regulatory principles concerning biological drugs and biosimilars that should be better communicated to Irish healthcare professionals.
The specialists indicated they had concerns about biosimilars that range from slight to extreme in relation to:
Most specialists surveyed (>95%) opposed pharmacist-led substitution of biological drugs, though some thought it could be appropriate if agreed to by the clinician in advance. In addition, specialists who prescribe biosimilars (n = 43) were more likely to do so on treatment initiation (67%) rather than in a switch from an originator medication to a biosimilar (28%).
The authors noted that, in Ireland, unlike other countries, there is currently no national guidance in relation to switching from an innovator drug to a biosimilar; if biosimilar uptake is to be encouraged in Ireland, further guidance about switching and how best to manage this practice may be needed. “Notably, 19% of medical specialists who currently prescribe biosimilars indicated that they would be likely to switch to a biosimilar when a patient's response to the reference medicine was inadequate,” the authors said. This response highlights the need to inform prescribers that biosimilars are equivalent treatments to their reference medicines, offering comparable patient outcomes.
Another challenge that the survey exposed is that only 14% of pharmacists stated that they were comfortable with substitution without prescriber agreement. As pharmacists are ultimately responsible for the implementation of substitution policies at the pharmacy level, the survey results suggest that pharmacists have reservations about assuming responsibility for substitution without prescriber agreement, which is a situation that must be addressed.
The study’s authors conclude that targeted communication to medical specialists via professional societies, published literature, and educational events could help to reduce the information gap about biosimilar medicines. The most appropriate communication channels for GPs and community pharmacists are not as clear, but communication with professional societies may facilitate the transfer of knowledge to these professionals.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.